Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Consero Healthcare General Counsel Forum 2026
Sponsorship
Antitrust
Energizing Tomorrow: The Future of Energy, Antitrust & International Business Law
Sponsorship
Antitrust
AHLA Antitrust in Health Care Conference
Webinar
Antitrust
IBA Annual Conference 2026
Sponsorship
Antitrust
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Survival vs. Antitrust: Inside the FTC’s Strict Standards for "Failing" Hospital Acquisitions
Axinn Viewpoints
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
Axinn Partners Named to Lawdragon’s 2027 500 “Leading Litigators in America” Guide
Awards & Recognitions
Antitrust
